Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis

Zhihui Jiang,1,2,*
Xianxia He,3,*
Jian Li2
1Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, China; 2Department of Pharmacy, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China; 3Department of Drug Certification, Center for Certification and Evaluation, Guangzhou Food and Drug Administration, Guangzhou, China
*These authors contributed equally to this work

Purpose: The main objective of our meta-analysis was to examine the in vitro synergistic effect of meropenem-based combination therapies against Acinetobacter baumannii through a systematic review of the existing literature.

Methods: An extensive search was performed with no restrictions on date of publication, language, and publication type. Our study evaluated the main conclusions drawn from various studies describing the synergistic activity of combination therapies in vitro.

Results: In this review, 56 published studies were included. Our report included data on 20 types of antibiotics combined with meropenem in 1,228 Acinetobacter baumannii isolates. In time-kill studies, meropenem combined with polymyxin B and rifampicin showed synergy rates of 98.3% (95% CI, 83.7%–100.0%) and 89.4% (95% CI, 57.2%–100.0%), respectively, for Acinetobacter baumannii, modest synergy rates were found for meropenem combined with several antibiotics such as colistin and sulbactam, and no synergy effect was displayed in the combination of meropenem and ciprofloxacin, whereas in checkerboard method, the synergy rates of polymyxin B and rifampicin were 37.0% (95% CI, 0.00%–100.0%) and 56.3% (95% CI, 8.7%–97.8%), respectively.

Conclusion: We found that time-kill studies generally identified the greatest synergy, while checkerboard and Etest methods yielded relatively poor synergy rates. Further well-designed in vivo studies should be carried out to confirm these findings.

Keywords: Acinetobacter baumannii, meropenem, synergy, combination, in vitro

Introduction
The spread of Acinetobacter baumannii (A. baumannii), a major pathogen responsible for hospital infections, is difficult to control and its infections are difficult to treat owing to its ability to adapt to different environments and its intrinsic resistance to many antibiotics.1 Furthermore, an increasing number of multi-drug-resistant (MDR), even pan-drug-resistant A. baumannii strains have been isolated.2 Infections caused by MDR A. baumannii primarily occur in immunosuppressed patients, in patients with serious underlying diseases, and in those who underwent invasive procedures and treatment with broad-spectrum antibiotics.3 Meropenem, as a carbapenem antibiotic, has a low-toxicity profile and is highly resistant to serine β-lactamases produced by many MDR gram-negative bacteria, thus playing a key role in the treatment of various infections that are not readily treated by other antibiotics.4 However, reports regarding the yearly increase in meropenem-resistant A. baumannii strains have captured the attention of clinicians and microbiologists.5 A great focus has been placed on combination therapies to reduce A. baumannii resistance, and numerous experiments have been performed with
meropenem-based therapies. However, systematic analysis of meropenem-based combination therapies is still lacking. To provide a basis and reference for clinical rationales behind the in vitro synergistic activity of meropenem with other antibiotics against A. baumannii.

Materials and methods

Search strategy and selection criteria

A broad literature search was performed throughout March 2018 by two separate reviewers. Journal articles were selected without limitations on publication date, language, or publication type. Keywords and Boolean operators used for the searches were (meropenem) AND (baumannii) AND (synerg* OR combin*). We also used the related articles function to broaden our search. In addition, reference lists of the selected articles were also manually examined to find relevant studies that were not included in our initial searches.

All meropenem-based in vitro combinations tests (application of traditional testing methods including the checkerboard, Etest, and the time-kill method, which included both the static time-kill and the in vitro dynamic pharmacokinetic/pharmacodynamic model) were included in this study. Those testing meropenem in combination with compounds that are not available on the market worldwide, and the combination therapies with more than two drugs were excluded.

Data collection and statistical analysis

In this meta-analysis, data were independently extracted by two researchers using a premade data extraction form. From each study, the following information was extracted: 1) first author and the publication year; 2) susceptibility to meropenem; 3) types of antibiotics used; 4) total number of isolates tested; 5) in vitro combination testing methods. Antibiotic breakpoints were set based on the Clinical and Laboratory Standards Institute. Meropenem susceptibility and resistance were defined as susceptible, ≤2 mg/L; intermediate, 4 mg/L; resistant, ≥8 mg/L.

The outcome analyzed in the study was the in vitro synergy activity of combination therapy. For time-kill tests, synergy was defined as ≥2 log_{10} (at any time points in 24 hours) colony-forming units/mL decrease between the combination therapy and the most efficient agent, when used alone. With the checkerboard and Etest method, interactions were defined by the fractional inhibitory concentration index (FICI), which was calculated using the following formula: FICI = (MIC_{AB} / MIC_A) + (MIC_{BA} / MIC_B), where MIC_{AB} and MIC_{BA} were the minimum inhibitory concentrations (MIC) of drugs A and B in combination therapy, while MIC_A and MIC_B were the MIC of drugs A and B tested alone. The FICI value was interpreted as follows: ≤0.5, synergy; >0.5–4, indifference; >4, antagonism.

Synergy rates with 95% CI and each isolate reported in a paper were calculated separately for each synergy method, where the number of isolates tested was defined as the sample size and the event was defined as synergy. As the event rates in most studies are 0 or 1, which are not normally distributed, we performed a logit transformation for the event rates. Results from each testing method were subgrouped by antibiotic type. Some time-kill studies utilized multiple drug concentrations on the same bacterial strains, and we chose a more common clinically achievable drug concentration. For studies applying multiple test methods, data were collected and analyzed separately. All statistical analyses were performed with the Stata 14.0 software (Stata Corporation 2015, College Station, TX, USA). We calculated various pooled synergy rates by two separate reviewers. Journal articles were selected from each testing method were subgrouped by antibiotic type.

Results

Studies included

Our search strategy initially yielded 1,161 potentially relevant citations from PubMed, Embase, and Web of Science (Figure 1). Excluding the studies that did not report any in vitro experiments evaluating the synergistic effect of meropenem-based combinations against A. baumannii, 56 published studies fulfilled the inclusion criteria and were included in this review. The characteristics of each included study are described in Table 1. In the analysis, 1,228 A. baumannii strains were subjected to 14 Etests, 42 checkerboard microdilution tests, and 40 time-kill assays to evaluate the synergistic activity of meropenem combination therapies using 20 types of antibiotics.

Time-kill data synthesis

Meropenem–polymyxin B combination therapies (Figure 2) were assessed in ten studies using 30 isolates, and yielded a synergy rate of 98.3% (95% CI, 83.7%–100.0%) with no heterogeneity (F); the fixed-effect model was applied in the meta-analysis, and no isolates showed antagonism. As only one study was conducted on the meropenem-susceptible strains, subgroup analysis was not performed for this combination therapy.
For meropenem–rifampicin combinations (Figure 3), pooling data from 20 isolates in four studies showed that the synergy rate was 89.4% (95% CI, 57.2%–100.0%), and no antagonism was observed.\textsuperscript{16,20,24,32} Heterogeneity ($I^2$) for these studies was 51.9%; thus, the random-effect model was utilized in the analysis.

For meropenem–colistin combinations (Figure 4), tests conducted on 132 isolates in 12 studies yielded a synergy rate of 60.4% (95% CI, 24.7%–91.8%), and no isolate was antagonistic.\textsuperscript{7,14,15,21,23,44,47,53,54,56,61,62} Heterogeneity ($I^2$) was calculated to be 89.8%, and thus, the random-effect model was applied in the meta-analysis. There are five studies on meropenem-susceptible strains; however, no detailed information on the number of isolates was found in some of these studies, which resulted in the absence of subgroup analysis.

For meropenem–sulbactam combination therapies (Figure 5), tests were performed on 69 isolates in five studies, and yielded a synergy rate of 54.8% (95% CI, 39.7%–69.6%) with no heterogeneity ($I^2$), and the fixed-effect model was chosen.\textsuperscript{8,14,21,46,53} None of the isolates was antagonistic. Two studies evaluated the combination of meropenem and ampicillin/sulbactam, and synergy was observed in 0/1 and 1/2 strains, respectively.

For meropenem–tigecycline combinations (Figure S1), six studies were performed on 36 isolates, which yielded a synergy rate of 24.5% (95% CI, 1.0%–58.4%), and no antagonism was found and heterogeneity ($I^2$) for these studies was 46.5%.\textsuperscript{12,16,20,47,53,56}

Two studies on nine strains tested meropenem–amikacin combinations, and the synergistic effect was found in 0/1 and 8/8 strains, respectively. One study evaluated meropenem–ciprofloxacin combination, and the synergistic activity was found in 18/40 strains.

**Checkerboard microdilution data synthesis**

For meropenem–polymyxin B combinations (Figure 6), tests were carried out on 99 strains in four studies, and showed a pooled synergy rate of 37.0% (95% CI, 0.0%–100.0%) and heterogeneity ($I^2$) was 98.1%.\textsuperscript{13,26,39,51} Owing to its high
Table 1 Characteristics of included studies

| Study, year | Meropenem resistance | Combination antibiotics | No of isolates | Test method |
|-------------|----------------------|-------------------------|----------------|-------------|
| Ko et al,
2004     | R (MIC: 8 mg/L)      | Sulbactam (MIC: 8 mg/L) | 1 Tks          |             |
| Kiffe et al,
2005     | R (n=6); I (n=1); S (n=38) (MIC: 0.125 to >32 mg/L) | Sulbactam (MIC: 2 to >32 mg/L) | 48 Checkerboard |             |
| Sader et al,
2005     | R (n=4); S (n=1) (MIC: 1 to >8 mg/L) | Aztreonam (MIC: >8 mg/L) | 5 Tks         |             |
| Timurkaynak
et al,
2006     | R (n=1); I (n=1); S (n=3) (MIC: 1–64 mg/L) | Colistin (R=2, S=3) (MIC: 1–4 mg/L) | 5 Checkerboard |             |
| Scheetz et al,
2007     | NM                   | Tigecycline (MIC: 1 mg/L) | 1 Tks         |             |
| Gueffi et al,
2008     | R (n=5); I (n=1); S (n=4) (MIC: 0.5–256 mg/L) | Gatifloxacin (R=4, I=1, S=5, MIC: 0.03–8 mg/L) | 10 Checkerboard |             |
| Lee et al,
2008     | R (MIC: 256 or 64 mg/L) | Sulbactam (MIC: 128 or 16 mg/L) | 2 Tks         |             |
| Pankuch et al,
2008     | R (n=1 or 11); I (n=2); S (n=37 or 38) (MIC: 0.12 or 256 mg/L) | Ciprofloxacin (R=6, I=1, S=33, MIC: 0.06 or 256 mg/L) | 40 or 51 Tks |             |
| Lim et al,
2009     | R (MIC: 32 or 64 mg/L) | Polymyxin B (MIC: 1 or 2 mg/L) | 3 Tks         |             |
| Pankey et al,
2009     | R (MIC: 24 or >32 mg/L) | Polymyxin B (MIC: 0.5 mg/L) | 8 Tks, Etest |             |
| Kiratsin et al,
2010     | R (n=21); I (n=1); S (n=18) (MIC: 0.19 to >32 mg/L) | Rifampicin (MIC: 1–8 mg/L) | 40 Etest |             |
| Koerber-Irrgang et al,
2010     | NM                   | Daptomycin              | 10 Checkerboard |             |
| Lim et al,
2010     | R                   | Polymyxin B (MIC: 16–128 mg/L) | 5 Tks         |             |
| Pongpech et al,
2010     | R (MIC: 64–256 mg/L) | Tigecycline (R), rifampin (R), Cefepime | Tks         |             |
| Sarigüzel et al,
2010     | R (n=76); S (n=24) (MIC: 0.125 to >32 mg/L) | Cefoperazone/sulbactam (MIC: 0.25–256 mg/L) | 100 Etest |             |
| Srisuphaolarn et al,
2010     | R (MIC: 32–128 mg/L) | Colistin (MIC: 0.5–1 mg/L) | 3 PK/PD |             |
| Chopra et al,
2012     | R                   | Rifampicin              | 6 Checkerboard; Tks |             |
| Deveci et al,
2012     | R (n=9); S (n=1) (MIC: 2–64 mg/L) | Sulbactam (MIC: 32–1024 mg/L) | 10 Checkerboard |             |
| Ozseven et al,
2012     | R (MIC: 16–128 mg/L) | Ampicillin/sulbactam (MIC: 32–128 mg/L) | 34 Checkerboard |             |
| Netto et al,
2013     | R (MIC: 32 mg/L) | Cefoperazone/sulbactam (MIC: 32–512 mg/L) | 2 Tks |             |
| Turk Dagi et al,
2014     | R (n=31); I (n=9) (MIC: 4–64 mg/L) | Polymyxin B (MIC: 0.25 or 2 mg/L) | 40 Tks | Checkerboard |
| Franczak et al,
2014     | R                   | Colistin                | 5 Checkerboard |             |
| Lu et al,
2014     | R (MIC: 16–128 mg/L) | Sulbactam (MIC: 16–128 mg/L) | 50 Checkerboard |             |
| Shah et al,
2014     | R (MIC: >32 mg/L) | Cefoperazone/sulbactam (MIC: 32–256 mg/L) | 1 Etest |             |
| Sun et al,
2014     | R (MIC: 64 or 128 mg/L) | Aminophylline (MIC: 32–128 mg/L) | 12 Checkerboard; Tks |             |
| Xia et al,
2014     | R                   | Cefoperazone/sulbactam | 60 Checkerboard |             |
| Gall et al,
2015     | R                   | Polymyxin B (MIC: 0.5 mg/L) | 1 PD |             |
| Ke et al,
2015     | R (MIC: 16–64 mg/L) | Sulbactam (MIC: 16 or 256 mg/L) | 37 Checkerboard |             |
| (Continued) | | | | |
heterogeneity, we used the random-effect model for statistical analysis. No isolates were found to be antagonistic.

Thirteen studies with 189 isolates tested meropenem–colistin combination therapies and showed a pooled synergy rate of 58.8% (95% CI, 29.4%–85.6%) and a heterogeneity ($I^2$) of 92.3% (Figure 7); thus, the random-effect model was applied in the meta-analysis. Two isolates were found to be antagonistic. There are six studies that include meropenem-susceptible strains; however, no detailed number of isolates was found in some of these studies, which resulted in the unavailability of subgroup analysis.

### Table 1 (Continued)

| Study, year | Meropenem resistance | Combination antibiotics | No of isolates | Test method |
|-------------|----------------------|-------------------------|----------------|-------------|
| Le Minh et al,36 2015 | R (MIC: 0.19–128 mg/L) | Colistin (MIC: 0.047–0.75 mg/L) | 56 | Checkerboard |
| Marie et al,37 2015 | R (MIC: 16–1024 mg/L) | Sulbactam (MIC: 16–256 mg/L), tazobactam (MIC: 32–512 mg/L) | 54 | Checkerboard |
| Temocin et al,38 2015 | R (MIC: 16–32 mg/L) | Sulbactam (MIC: 2–256 mg/L) | 30 | Etest |
| Teo et al,39 2015 | R (MIC: 32 to >64 mg/L) | Polymyxin B (MIC: 0.5–2 mg/L) | 49 | Checkerboard |
| van Belkum et al,40 2015 | R (n=23); I (n=1); S (n=1) | Colistin (R=17, S=8, MIC: 1–8 mg/L) | 25 | Checkerboard |
| Vourli et al,41 2015 | R (MIC: 64–256 mg/L) | Amoxicillin/sulbactam (MIC: 128–256 mg/L) | 5 | Checkerboard |
| Yadav et al,42 2015 | S (MIC: 2 mg/L) | Tobramycin, amikacin | 1 | Tks |
| Bae et al,43 2016 | R (MIC: 32–256 mg/L) | Colistin (MIC: 8–1024 mg/L) | 9 | Checkerboard |
| Bedenic et al,44 2016 | RI | Colistin (S) | 8 | Checkerboard; Tks |
| Hong et al,45 2016 | R (MIC: 8 to >32 mg/L) | Colistin (R=41, S=41, MIC: 0.1 to >256 mg/L) | 82 | Etest |
| Laishram et al,46 2016 | R (MIC: 16–128 mg/L) | Sulbactam (MIC: 16–128 mg/L) | 50 | Checkerboard; Tks |
| Leite et al,47 2016 | R (MIC: 16–128 mg/L) | Colistin (R=7, S=13, MIC: 0.5–64 mg/L) | 20 | Checkerboard |
| Lenhard et al,48 2016 | R (MIC: 64–128 mg/L) | Polymyxin B (S) | 2 | Tks |
| Liu et al,49 2016 | R (MIC: 16–128 mg/L) | Colistin (MIC: 0.5–2 mg/L) | 12 | Checkerboard |
| Lenhard et al,50 2016 | R (n=2); I (n=1); (MIC: 4–64 mg/L) | Polymyxin B (MIC: 0.5 mg/L) | 3 | Tks |
| Menegucci et al,51 2016 | R (MIC: 64–128 mg/L) | Polymyxin B (R=3, S=3, MIC: 0.5–16 mg/L) | 6 | Checkerboard |
| Wang et al,52 2016 | R | Cefoperazone/sulbactam, sulbactam (R), amikacin (R), ciprofloxacin (R) | 116 | Checkerboard |
| Wang et al,53 2016 | R (n=3); S (n=3); (MIC: 0.5–64 mg/L) | Colistin (MIC: 0.5–2 mg/L) | 6 | Tks |
| Yang et al,54 2016 | R (MIC: 8–128 mg/L) | Colistin (MIC: 0.5 mg/L) | 4 | Checkerboard; Tks |
| Yavaş et al,55 2016 | R (MIC: ≥32 mg/L) | Minocycline (MIC: 16 or 32 mg/L) | 18 | Etest |
| Büyükk et al,56 2017 | RIS | Colistin, tigecycline | 15 or 1 | Checkerboard; Tks |
| Gallo et al,57 2017 | S (MIC: 0.25 or 1 mg/L) | Polymyxin B (MIC: 0.5 or 1 mg/L) | 3 | Tks |
| Ghazi et al,58 2017 | R (MIC: ≥64 mg/L) | Amikacin (MIC: 64–512 mg/L) | 8 | Tks |
| Lenhard et al,59 2017 | R (MIC: 64 mg/L) | Ampicillin/sulbactam (MIC: 32/16 mg/L) | 1 | Tks |
| Lenhard et al,60 2017 | R (MIC: 64 mg/L) | Ampicillin/sulbactam (MIC: 32/16 mg/L) | 2 | Tks |
| Manohar et al,61 2017 | R (MIC: >128 mg/L) | Colistin (MIC: 32 mg/L) | 2 | Tks |
| Soudeia et al,62 2017 | RIS | Colistin (RS) | 21 | Checkerboard; Etest; Tks |
| Tangden et al,7 2017 | R (n=2); S (n=2); (MIC: 0.5–32 mg/L) | Colistin (MIC: 0.125–1.5 mg/L) | 4 | Checkerboard; Tks |

**Abbreviations:** I, intermediate; MIC, minimum inhibitory concentration; NM, not mentioned; PK/PD, pharmacokinetic/pharmacodynamic; R, resistant; S, susceptible; Tks, time-kill synergy.
As shown in Figure 8, tests conducted on 405 isolates in eight studies showed that the synergy rate of meropenem–sulbactam combinations was 25.2% (95% CI, 16.1%–36.2%). A static heterogeneity ($I^2$) of 79.4% was observed, and as a result, we chose the random-effects model. Three isolates were antagonistic. Considering that there was no detailed number of meropenem-susceptible isolates in three studies, the subgroup analysis was not applied. Six studies were performed on 309 strains in the meropenem–cefoprazone/sulbactam combinations (Figure S2), yielding a pooled synergy rate of 7.4% (95% CI, 1.4%–16.6%). Heterogeneity ($I^2$) for these studies was 80.6%. Two studies testing meropenem–rifampicin combination therapies (Figure S3) yielded a synergy rate of 56.3% (95% CI, 8.7%–97.8%). Heterogeneity ($I^2$) for these studies was 90.2%. Meropenem–ciprofloxacin combination therapies were tested in three studies (Figure S4), and yielded a pooled synergy rate of 0.3% (95% CI, 0.0%–3.5%).

Heterogeneity ($I^2$) was 33.0%. The combination of meropenem and tigecycline was tested in two studies, and seven of 35 strains showed synergy. Two studies tested the effect of meropenem in combination with amikacin, and synergistic activity was found in 67/128 strains.

**Etest data synthesis**

Four studies that evaluated the effect of meropenem–colistin combinations (Figure S5) on 122 isolates yielded a pooled synergy rate of 39.2% (95% CI, 0.0%–97.7%), and heterogeneity ($I^2$) was found to be 95.9%. Three studies consisting of 102 strains investigated the effect of meropenem–sulbactam combinations (Figure S6), reporting a pooled synergy rate of 35.1% (95% CI, 21.4%–50.1%). Heterogeneity ($I^2$) was 52.3%. One study with 40 strains tested the meropenem–rifampicin and meropenem–moxifloxacin combinations, and synergy was found in 1 and 0 strain, respectively. Two studies reported synergistic effect
In vitro meropenem-based combination against *A. Baumannii*

**Figure 3** Forest plot and pooled synergy rates for meropenem–rifampicin combinations in time-kill method.
*Abbreviation:* ES, effect size.

| Study               | ES (95% CI)         | Weight |
|---------------------|---------------------|--------|
| Lim et al,\(^16\) 2009 | 0.333 (0.008–0.906) | 19.93  |
| Lim et al,\(^20\) 2010 | 0.800 (0.284–0.995) | 25.35  |
| Chopra et al,\(^24\) 2012 | 1.000 (0.541–1.000) | 27.36  |
| Sun et al,\(^32\) 2014 | 1.000 (0.541–1.000) | 27.36  |
| Overall (\(I^2 = 51.924\%, \(P = 0.100\)) | 0.894 (0.572–1.000) | 100.00 |

**Figure 4** Forest plot and pooled synergy rates for meropenem–colistin combinations in time-kill method.
*Abbreviation:* ES, effect size.

| Study               | ES (95% CI)         | Weight |
|---------------------|---------------------|--------|
| Tangden et al,\(^7\) 2017 | 0.604 (0.247–0.916) | 100.00 |
| Srisupha-Olarn et al,\(^23\) 2010 | 0.000 (0.000–0.602) | 8.14   |
| Wang et al,\(^53\) 2016 | 1.000 (0.832–1.000) | 9.66   |
| Yang et al,\(^36\) 2016 | 0.500 (0.013–0.987) | 7.01   |
| Yang et al,\(^36\) 2016 | 0.961 (0.665–0.999) | 9.98   |
| Pongpech et al,\(^31\) 2010 | 0.900 (0.555–0.997) | 9.20   |
| Srisupha-Olarn et al,\(^35\) 2010 | 1.000 (0.292–1.000) | 7.70   |
| Bedenic et al,\(^46\) 2016 | 0.625 (0.245–0.915) | 9.00   |
| Lee et al,\(^14\) 2008 | 1.000 (0.832–1.000) | 9.66   |
| Parkuch et al,\(^15\) 2008 | 0.550 (0.001–0.987) | 7.01   |
| Pongpech et al,\(^31\) 2010 | 0.961 (0.665–0.999) | 9.98   |
| Srisupha-Olarn et al,\(^35\) 2010 | 0.900 (0.555–0.997) | 9.20   |
| Bedenic et al,\(^46\) 2016 | 1.000 (0.292–1.000) | 7.70   |
| Lee et al,\(^46\) 2016 | 0.625 (0.245–0.915) | 9.00   |
| Wang et al,\(^53\) 2016 | 1.000 (0.832–1.000) | 9.66   |
| Yang et al,\(^36\) 2016 | 0.500 (0.013–0.987) | 7.01   |
| Böyük et al,\(^36\) 2017 | 0.750 (0.194–0.994) | 8.14   |
| Monarch et al,\(^46\) 2017 | 1.000 (0.025–1.000) | 5.80   |
| Soudiha et al,\(^45\) 2017 | 0.143 (0.030–0.363) | 9.69   |
| Tangden et al,\(^3\) 2017 | 0.000 (0.000–0.842) | 7.01   |
| Overall (\(I^2 = 89.803\%, \(P = 0.000\)) | 0.604 (0.247–0.916) | 100.00 |

*Abbreviation:* ES, effect size.
**Figure 5** Forest plot and pooled synergy rates for meropenem–sulbactam combinations in time-kill method. Abbreviation: ES, effect size.

**Figure 6** Forest plot and pooled synergy rates for meropenem–polymyxin B combinations in checkerboard method. Abbreviation: ES, effect size.
of 23/100 strains in meropenem–tigecycline combination therapies. Meropenem in combination with cefoprazone/sulbactam resulted in synergistic activity in 61/140 strains.

**Discussion**

The global emergence of MDR *A. baumannii* has spurred an interest in finding a more effective treatment strategy. The World Health Organization has identified antimicrobial resistance as one of the three most important problems affecting human health and carbapenem-resistant *A. baumannii* as a critical priority pathogen to help in prioritizing the research and development of new and effective antibiotic treatments. Combining antimicrobials is an effective treatment approach for MDR *A. baumannii* infections. Reports of meropenem-based combination against *A. baumannii* have been rising steadily during the past few years. Our results indicated that several antibiotics combined with meropenem could act synergistically in vitro against *A. baumannii*, especially for polymyxin B and rifampicin. Notably, colistin, also known as polymyxin E, showed a lower synergy rate than polymyxin B in the time-kill assays, while an opposite result was found in the checkerboard microdilution method. Several reasons could result in the inconsistent result. First, polymyxin B and colistin are mixture of cyclic polypeptides, which contain up to 39 and 36 distinct lipopeptides, respectively, and differences in the structures of these individual polypeptides and variations in the physicochemical property among different polymyxin products or even batches from the same company can contribute to variability in the antibacterial activity of polymyxin B and colistin. Second, the small sample size may skew the result though we performed a logit transformation for the event rate. Third, the time-kill method uses colony number as the judgment standard, while checkerboard microdilution and Etest methods use MIC in the formula. With no standardization of synergy test method, comparing results generated from different methods becomes a difficult
As demonstrated in Table 2, it seems that higher rates of synergy are seen with time-kill assays than with checkerboard or Etest assays, which is consistent with the conclusion drawn by Ni et al.65 The synergy rate obtained from checkerboard microdilution and Etest methods is a static value and hard to reproduce.66 In terms of time-kill assay, it is a useful method to provide us kinetic information of antibiotic interaction with bacteria although time- and labor-intensive for routine use in a clinical diagnostic laboratory. Therefore, developing new kinetic test method such as luciferase-based reporter system or standardizing the interpretation of these existing test methods for synergy evaluation should be a feasible strategy to address these limitations.

In time-kill assays, meropenem–polymyxin B combination showed the highest pooled synergy rate of 98.3%, which can be recognized as a very high degree of synergy to almost all isolates with different resistant profiles. Rifampicin in combination with meropenem displayed up to approximately 90% high synergy rate, and it is worth noting that amikacin may be a good partner of meropenem though only two studies can be found. Polymyxin B and amikacin are both molecules containing cations, which are capable of binding negatively charged lipopolysaccharides in the outer membrane of gram-negative bacteria, which thus leads to disruption of bacterial membrane permeability.67 As to rifampicin, more studies should be conducted to confirm our preliminary finding, and the underlying mechanism of the combination also needs to be addressed. Polymyxins are considered as the last-resort antibiotic for the treatment of gram-negative bacteria; however, they were also reported to be associated with nephrotoxicity and neurotoxicity,68 which often hindered their use in clinical settings. To reduce their toxicity, purification of polymyxins product and structure modification have been reported by several groups.64

Sulbactam, as a member of serine β-lactamase inhibitor, is unable to inhibit any carbapenemases but displays moderate activity against A. baumannii, so a pooled synergy rate of 54.8% generated by meropenem–sulbactam combination was expected. Carbapenemases, especially metallo β-lactamases (MBLs), have caused extensive concern on their rapid dissemination and ability to hydrolyze almost all β-lactam antibiotics except monobactams. Unfortunately, up till now, no

| Study                  | ES (95% CI)  | %     | Weight |
|------------------------|--------------|-------|--------|
| Kiffer et al,5 2005    | 0.292 (0.170–0.441) | 13.07 |
| Deveci et al,25 2012   | 0.000 (0.000–0.308)   | 7.47  |
| Turk Dagi et al,26 2014| 0.475 (0.315–0.639) | 12.55 |
| Lu et al,20 2014       | 0.260 (0.146–0.403)   | 13.18 |
| Ke et al,25 2015       | 0.108 (0.030–0.254)   | 12.32 |
| Marie et al,37 2015    | 0.444 (0.309–0.586)   | 13.37 |
| Laishram et al,46 2016 | 0.320 (0.195–0.467) | 13.18 |
| Wang et al,52 2016     | 0.172 (0.109–0.254)   | 14.87 |
| Overall (I² = 79.433%, P = 0.000) | 0.256 (0.161–0.362) | 100.00 |

Figure 8 Forest plot and pooled synergy rates for meropenem–sulbactam combinations in checkerboard method. Abbreviation: ES, effect size.
Table 2 Summary of the pooled synergy rates

| Meropenem-based combinations | Tks | Checkerboard | Etest |
|-----------------------------|-----|--------------|-------|
| Polymyxin B                 | 10  | 30           | 4     | 99  | 37.0% (95% CI, 0.0%–100.0%) |
| Colistin                    | 12  | 132          | 13    | 189 | 58.8% (95% CI, 29.4%–85.6%) |
| Rifampicin                  | 4   | 20           | 3     | 52  | 56.3% (95% CI, 8.7%–97.8%) |
| Tigecycline                 | 6   | 36           | 2     | 35  | 7/35 |
| Sulbactam                   | 5   | 69           | 8     | 405 | 25.2% (95% CI, 16.1%–36.2%) |
| Cefoprazone/ sulbactam      | 0   | 0            | 6     | 309 | 7.4% (95% CI, 1.4%–16.6%) |
| Ciprofloxacin               | 1   | 40           | 3     | 178 | 0.3% (95% CI, 0.0%–3.5%) |
| Amikacin                    | 2   | 9            | 2     | 128 | 67/128 |

Abbreviation: Tks, time-kill synergy.

MBL inhibitor has been clinically approved and all clinically used β-lactamase inhibitors are not active toward MBLs. It remains a substantial challenge to design MBL inhibitors, especially for broad-spectrum MBL inhibitors.

Conclusion
The pooled synergy data in this review suggested that combination therapies of meropenem with polymyxin B, rifampicin, and possibly amikacin as well could achieve high synergy rates against MDR A. baumannii isolates, and colistin and sulbactam could be secondary choice for the combination with meropenem. Tigecycline and ciprofloxacin combination had the least pooled synergy rates. Compared to static checkerboard and Etest method, time-kill assay is more like in vivo dynamic antibacterial process and generally exhibited the greatest of synergisms because of its kinetic synergy calculation method. Combination therapies are future alternatives to traditional monotherapies for infections caused by MDR bacteria. However, the studies included in this review were performed in vitro, which neglects the complicated interactions between antibiotics and hosts. There is still a long way from our results to their applications in clinic, and findings of this review should be verified by more well-designed in vitro and in vivo studies.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (81403084); the Science and Technology Program of Guangzhou, China (201710010013 and 201509010012).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102.
2. Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017;64(Suppl 1):S30–S35.
3. Dijkstraen L, Neman A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951.
4. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenem: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960.
5. El-Gamal MI, Brabham I, Hisham N, Aladdin R, Mohammed H, Bahaeldin A. Recent updates of carbapenem antibiotics. Eur J Med Chem. 2017;131:185–195.
6. Falagas ME, Mavrodiadis AD, Vardakas KZ. The antibiotic pipeline for multidrug-resistant Gram-negative bacteria: what can we expect? Expert Rev Anti Infect Ther. 2016;14(8):747–763.
7. Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis. 2017;49(7):521–527.
8. Ko WC, Lee HIC, Chiang SR, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53(2):393–395.
9. Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2005;52(4):317–322.
24. Chopra S, Matsuyama K, Tran T, Madrid P. Systematic discovery of
23. Srisupha-Olarn W, Burgess DS. Activity of meropenem and colistin
22. Sarigüzel FM, Sümerkan B, Metan G. In-vitro activity of carbapenem/
20. Lim TP, Lee W, Sasikala S, et al. In vitro activity of antimicrobials in
16. Lim TP, Tan TY, Lee W, et al. In vitro activity of various combinations
15. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem
13. Guelfi KC, Tognim MC, Cardoso CL, Gales AC, Carrara-Marrone
12. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimi-
10. Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam
9. Guelfi KC, Tognim MC, Cardoso CL, Gales AC, Carrara-Marrone
8. Tran T, Maduro P, Madrid P. Activity of carbapenems in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii. Microbiol. 2014;48(2):311–315.
7. Frantzesskaki F, Vourli S, Paramythiotou E, et al. In vitro and in vivo synergistic activity of high doses of ampicillin/sulbactame with colistin versus meropenem with colistin in ventilator-associated pneumonia (VAP) caused by acinetobacter baumannii (AB). Intens Care Med. 2014;40(1):S195.
6. Lu Y, Zhang Y, Zhou H, Yu F, Sun S, Rui Y. Combined drug sensitivity test of 50 strains of extensively drug-resistant Acinetobacter baumannii. Nan Fang Yi Ke Da Xue Xue Bao. 2013;34(11):1697–1701.
5. Shah PG, Shah SR, Kamat SD, Kamat DV. Colistin-carbapenem combination therapy against carbapenem resistant gram negative bacilli infections: Clinical and an in vitro synergy study. Int J Pharm Pharmaceut Sci. 2014;6(10):497–500.
4. Sun Y, Wang L, Li J, et al. Synergistic efficacy of meropenem and rifampicin in a murine model of sepsis caused by multidrug-resistant Acinetobacter baumannii. J Antimicrob Agents. 2013;62(12):675–679.
3. Marie MA, Krishnapa L.G, Alzahrani AJ, Mubaraki MA, Alyousef AA. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of ceftazidime/sulbactam. Int J Infect Dis. 2014;23:90–93.
2. Gall J, Lenhard J, Holden PN, Tsuji BT. Comparative pharmacodynamics of imipenem, doripenem, meropenem, and ertapenem in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. Pharmacotherapy. 2015;35(11):c304–c305.
1. Ke Q, Lü Y, Wang F. In vitro activity of meropenem in combination with sulbactam or ceftazidime/sulbactam against multidrug resistant acinetobacter baumannii. Chin J Infect Chemother. 2015;15(6):548–551.

44. Bedenić B, Beader N, Godić-Torkar K, et al. Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms. J Chemother. 2016;28(5):375–382.
45. Hong DJ, Kim JO, Lee H, et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2016;86(2):184–189.
46. Laishram S, Anandan S, Devi BY, et al. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance. J Chemother. 2016;28(4):297–303.
47. Leite GC, Oliveira MS, Perdigão-Neto LV, et al. Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms. PLoS One. 2016;11(3):e0151270.
48. Lenhard JR, Bulitta JB, Connell TD, et al. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Agents. 2017;72(1):153–165.
49. Liu X, Zhao M, Chen Y, et al. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents. 2016;48(5):559–563.
50. Lenhard JR, Gall JS, Bulitta JB, et al. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48(6):719–724.
51. Menegucci TC, Albiero J, Migliorini LB, et al. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2016;47(5):380–385.
52. Wang FJ, Lyu Y, Liu ZH, Li Y, Cui LQ. In vitro activity of different antibacterial agents in combination with each other against multidrug-resistant Acinetobacter baumannii. Chin Med J. 2016;129(19):2388–2389.
53. Wang YC, Kuo SC, Yang YS, et al. Individual or combined effects of meropenem, imipenem, sulbactam, colistin, and tigecycline on biofilm-embedded Acinetobacter baumannii and biofilm architecture. Antimicrob Agents Chemother. 2016;60(8):4670–4676.
54. Yang YS, Lee Y, Tseng KC, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(7):4047–4054.
55. Yayva S, Yetkin MA, Kayaslan L, et al. Investigating the in vitro synergistic activities of several antibiotic combinations against carbapenem-resistant Acinetobacter baumannii isolates. Turk J Med Sci. 2016;46(3):892–896.
56. Büyü̈k A, Yilmaz FF, Gül Yurtsever S, Höggor Limoncu M. Antibiotic resistance profiles and genotypes of Acinetobacter baumannii isolates and in vitro interactions of various antibiotics in combination with tigecycline and colistin. Turk J Pharm Sci. 2017;14(1):13–18.
57. Gallo SW, Ferreira CAS, de Oliveira SD. Combination of polymyxin B and meropenem eradicates persistor cells from Acinetobacter baumannii strains in exponential growth. J Med Microbiol. 2017;66(8):1257–1260.
58. Ghazi IM, Grupper M, Niclou DP. Antibacterial activity of human-simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii. In Vitro Antimicrob Agents. 2017;49(11–12):831–839.
59. Lenhard JR, Smith NM, Bulman ZP, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61(3):e01268-16.
60. Lenhard JR, Thamlikitkul V, Silveira FP, et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017;72(5):1415–1420.
61. Manohar P, Shanthini T, Ayyanar R, et al. The distribution of carbapenem- and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India. J Med Microbiol. 2016;65(7):874–883.
62. Soudeilha MAH, Dahdouh EA, Azar E, Sarkis DK, Dassou D. In vitro evaluation of the colistin-carbapenem combination in clinical isolates of A. baumannii using the checkerboard, Etest, and time-kill curve techniques. Front Cell Infect Microbiol. 2017;7:209.
63. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Geneva: World Health Organization; 2017.
64. Roberts KD, Azad MA, Wang J, et al. Antibacterial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect Dis. 2015;1(11):568–575.
65. Ni W, Shao X, Xi C, Cui J, Wang R, Li Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45(1):8–18.
66. Rand KH, Houck HJ, Brown P, Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother. 1993;37(3):613–615.
67. Yadav R, Bulitta JB, Schneider EK, Shin BS, Velkov T, Nation RL, Landersdofer CB. Aminoglycoside concentrations required for synergy with carbapenems against Pseudomonas aeruginosa determined via mechanistic studies and modeling. Antimicrob Agents Chemother. 2017;61(12):e00722-17.
68. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Eur Soc Clin Microbiol Infect Dis. 2012;18(1):18–29.